- Conditions
- Cognitive Dysfunction, Schizophrenia
- Interventions
- KYN-5356, placebo
- Drug
- Lead sponsor
- Kynexis B.V.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Glendale, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cognitive Impairment Associated With Schizophrenia (CIAS)
- Interventions
- KYN-5356 low dose, Placebo, KYN-5356 Medium Dose, KYN-5356 High Dose
- Drug · Other
- Lead sponsor
- Kynexis B.V.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 12 more